


BERIPLEX® RECONSTITUTION¹


Mix2Vial™ Instructions

STEP 1



Place WFI vial on a level surface and hold firmly
Pierce the WFI vial

STEP 2



Pull out the package and invert WFI vial

STEP 3




Hold the product firmly on a level surface
Pierce the powder vial (WFI flows automatically)

INCORRECT CONNECTION METHODS





STEP 4



Unscrew Mix2Vial™ and WFI vial by turning anti-clockwise
Gently swirl until dissolved

STEP 5



Draw reconstituted product into syringe

WFI = Water for Injection vial.
For detailed instructions on reconstitution and administration, see package insert.

Beriplex®

Human Prothrombin Complex



PBS Information: This product is not listed on the PBS. This product is funded under arrangements implemented by the National Blood Authority. Please refer to the National Blood Authority for details.

Before prescribing, please review Product Information.
The Product Information can be accessed at www.cslbehring.com.au/au-PI

MINIMUM PRODUCT INFORMATION Beriplex® P/N (Human prothrombin complex) contains factors II, VII, IX & X, proteins C & S. **INDICATIONS:** Treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required. **CONTRAINDICATIONS:** Hypersensitivity to active substances or excipients; history of heparin-induced thrombocytopenia (HIT); in disseminated intravascular coagulation (DIC), only apply after termination of consumptive state. **PRECAUTIONS:** Risk of thrombosis or DIC, particularly with repeated dosing or in patients with predisposition. Risk of hypersensitivity and HIT type II. Made from human plasma, may contain infectious agents, risk of transmission reduced by donor screening and manufacturing procedures. Use in neonates, children, pregnancy or lactation not established. Consider product heparin content when performing clotting tests. **INTERACTIONS:** Neutralises effect of vitamin K antagonists. **ADVERSE EFFECTS:** Headache, hypotension, thromboembolic events, nausea/vomiting, anaemia, body temperature increased, tachycardia, hypokalemia, insomnia, pleural effusion, atrial fibrillation, skin laceration/subcutaneous haematoma, respiratory distress/dyspnea/hypoxia, fluid overload, diarrhoea, pulmonary oedema. **DOSAGE & ADMINISTRATION:** Initiate treatment under supervision of coagulation disorders specialist. Dose based on algorithm adjusted for patient's body weight, clinical condition and response (approximate dose range 25-50 IU/kg or 1-2 mL/kg); regular monitoring (eg. International Normalised Ratio (INR)) required. Administer intravenously via separate injection/infusion line at maximum rate of 3 IU/kg/min (approximately 8mL/min). Refer to full PI for further information. Contains no preservative, recommended to use immediately after reconstitution. [minPI v2; AU-BAU-0018].

Reference: 1. BERIPLEx® Product Information.

BERIPLEx® is a registered trade mark of CSL Limited. For information: CSL Behring (Australia) Pty Ltd: For Medical/Technical Inquiries: Phone 1800 642 865. For Customer Service Inquiries: Phone 1800 063 892. E-mail: customerservice@cslbehring.com.au. Internet: www.cslbehring.com.au. CSL Behring (Australia) Pty Ltd 655 Elizabeth Street, Melbourne, Vic, 3000. ABN: 48 160 734 761. May 2024. AU-BAU-0022. 002217